Steroid sidestep: Evading androgen ablation by abiraterone - Abstract

Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well-defined.

Chen and colleagues report that a T878A androgen receptor mutation occurs in subset of patients progressing while receiving abiraterone, suggesting this may be a therapeutically exploitable mechanism of abiraterone resistance in castration-resistant prostate cancer (CRPC).

Written by:
Sharifi N.   Are you the author?
Cancer Biology, Cleveland Clinic.  

Reference: Clin Cancer Res. 2014 Nov 28. pii: clincanres.2899.2014.
doi: 10.1158/1078-0432.CCR-14-2899

PubMed Abstract
PMID: 25432158 Prostate Cancer Section